BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B)
Breast Cancer · 2026-05 · 33 (3) · 790-797
DOI: 10.1007/s12282-026-01855-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Breast Cancer, online erschienen am 10.04.2026. Verfasst von Hitomi Sakai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. sakai-h@med.showa-…. Hauptthemen laut MEDLINE: BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SHOWA Medical University.
Abstract (Originalsprache)
Background
A key resistance mechanism to PARP inhibitors is the development of BRCA1/2 reversion mutations that restore the protein function.
Methods
Patients with metastatic breast cancer and germline BRCA1/2 mutations were recruited from 14 institutions and treated with olaparib. Targeted next-generation sequencing was performed on circulating tumor DNA (ctDNA) extracted from blood collected at base line and progression on olaparib (Guardant360). The primary objective was to evaluate the frequency of BRCA1/2 reversion mutations in this group.
Results
From November 2021 to October 2023, 60 patients were enrolled. The median age was 50.5 years (32–85). Of these, 12 (20.0%) had germline BRCA1 mutation and 48 (80.0%) had germline BRCA2 mutation. The median number of prior chemotherapies was 2 (0–7). Two patients had received platinum. Among patients with tumor progression on olaparib who had available ctDNA results, BRCA1/2 reversion mutations were identified in 25.0% (2/8; 95% CI 3.2–65.1%) with germline BRCA1 mutation and 23.5% (8/34, 95% CI 10.7–41.2%) with germline BRCA2 mutation. In one patient, BRCA2 reversion mutations were found in ctDNA seven months before radiological confirmation of progression on olaparib and again after progression. Among the ten cases with BRCA1/2 reversion mutations, all but one case involved secondary indels on primary indel sites. Reversion mutations were not observed in the C-terminal regions of BRCA1/2 .
Conclusion
BRCA1/2 reversion mutations were detected in ctDNA as a mechanism of resistance to olaparib. Certain genomic regions and mutation types appeared to be particularly prone to reversion mutations. Clinical trial registration UMIN000046007.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. sakai-h@med.showa-u.ac.jp.
- Advanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
- Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan.
- Department of Breast Surgery, Gifu University Hospital, Gifu, Japan.
- Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Förderung
- SHOWA Medical University
Zitieren
APA
Sakai, H., Kusumoto-Matsuo, R., Hosonaga, M., Nozawa, K., Futamura, M., Tanabe, Y., Mukohara, T., Shiraishi, K., Toyama, T., Yasojima, H., Watanabe, N., Sakai, H., Iwasa, T., Takeuchi, N., Tada, H., Sakai, K., Chiba, N., Takano, T., & Tsurutani, J. (2026). BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B). Breast Cancer, 33(3), 790-797. https://doi.org/10.1007/s12282-026-01855-2
Vancouver
Sakai H, Kusumoto-Matsuo R, Hosonaga M, Nozawa K, Futamura M, Tanabe Y, et al. BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B). Breast Cancer. 2026;33(3):790-797. doi:10.1007/s12282-026-01855-2
BibTeX
@article{Sakai2026,
author = {Sakai, Hitomi and Kusumoto-Matsuo, Rika and Hosonaga, Mari and Nozawa, Kazuki and Futamura, Manabu and Tanabe, Yuko and Mukohara, Toru and Shiraishi, Kazuhiro and Toyama, Tatsuya and Yasojima, Hiroyuki and Watanabe, Noriyuki and Sakai, Hideki and Iwasa, Tsutomu and Takeuchi, Nobumichi and Tada, Hiroshi and Sakai, Kazuko and Chiba, Natsuko and Takano, Toshimi and Tsurutani, Junji},
title = {BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B)},
journal = {Breast Cancer},
year = {2026},
volume = {33},
number = {3},
pages = {790--797},
doi = {10.1007/s12282-026-01855-2}
}
EUVIMED